Tech Giant Slack is set to IPO through a direct listing this month. It will be trading under the symbol "SK" and marks the continuation of multi billion dollar valued tech giants going public with … [Read more...] about Slack Direct Listing, Gold Mine Or Money Pit?
The past two months have been eventful for my number one stock pick ADMA Biologics (Nasdaq: ADMA). Moreover, on Friday May 24th, 2019 I added a new stock to the MS portfolio- Regenxbio (Nasdaq: RGNX). … [Read more...] about Portfolio Update: ADMA Biologics
Background We recently covered Uber and some of the headwinds they are facing. Since this research was released, few to none of the headwinds have been adequately addressed and the share price has … [Read more...] about UBER Update
Each year as we approach summer, biotech investors search for the elusive companies that will have the largest pops at the summer oncology conferences in order to reap the rewards of their play. We … [Read more...] about Why I am Buying Seattle Genetics
On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It
A popular idea floating around the biotech community is that healthcare companies are insulated, or more so at least than other sectors, from a trade war with China. From a fundamental perspective, … [Read more...] about Biopharma Stock Watch May 27th-31st
Sometimes during the lifetime of a company significant shifts in priorities and resource allocation are made. I believe the ability to recognize the need for such changes and the wherewithal to carry … [Read more...] about DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
In this next article in our series on investing in NASH I want to jump to the other end of the spectrum. In "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I painted a … [Read more...] about A High-Risk, High-Reward Biotech Stock Targeting NASH Cirrhosis
In my previous article "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I laid out my rationale for investing in NAFLD/NASH companies. I reasoned that by investing in … [Read more...] about An Attractive Biotech Stock Gunning For NASH
Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on … [Read more...] about INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review